FDA notifications. NRTI Emtriva receives FDA approval.
The Food and Drug Administration has approved Emtriva (FTC, emtricitabine), a new nucleoside reverse transcriptase inhibitor to be used in combination with other antiretroviral agents for the treatment of patients with HIV infection.
D000328:Adult; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D000068679:Emtricitabine